Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...

Compared with previous surgical iterations of the procedure, explains Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital, newer and FDA-approved catheter-based ...

Posters presented at the ASPC 2025 Congress on Cardiac Prevention showed the benefit of participating in cardiac rehabilitation for a variety of cardiac issues.

Investigators discuss how their findings on ovarian cancer mortality trends can guide earlier detection and prevention ...

A lively debate on the pros and cons of using hormone therapy in women to prevent cardiovascular events had attendees engaged throughout.

Varsha Tanguturi, MD, MPH, cardiologist and DETECT AS investigator, presented new data on how the findings she and her colleagues saw indicate almost universal increases in rates of aortic valve ...

Khush Kharidia, MD, a third-year internal medicine resident at UT Southwestern, presented the oral abstract, “Evaluating the Quality, Accuracy and Health Impact of Cholesterol-Related Content on ...

Generative AI aids in preventive cardiology by generating patient messages, interpreting data, and addressing healthcare access and treatment gaps, though misinformation remains a concern.

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to ...

Experts provided insights into how past cohort studies have helped to shape preventive medicine for more than 50 years.